Antibody-Antibiotic Conjugates: A Novel Therapeutic Platform against Bacterial Infections

Trends Mol Med. 2017 Feb;23(2):135-149. doi: 10.1016/j.molmed.2016.12.008. Epub 2017 Jan 23.

Abstract

Antibodies are potent components of the immune repertoire and have been successfully exploited to treat bacterial infections. Recently an antibody-antibiotic conjugate (AAC) that combines key attributes of an antibody and antibiotic has been shown to be efficacious against Staphylococcus aureus infection. An AAC has three components: an antibiotic payload to kill bacteria, an antibody to target delivery of the payload to bacteria, and a linker attaching the payload to the antibody. With increasing understanding of the biology and pathophysiology of S. aureus, this article highlights how this knowledge has led to the design principles of an efficacious AAC, and discusses how the AAC platform could be translationally applied to treat other perilous infectious diseases.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Humans
  • Immunoconjugates / pharmacokinetics
  • Immunoconjugates / pharmacology
  • Immunoconjugates / therapeutic use*
  • Staphylococcal Infections / drug therapy*
  • Staphylococcal Infections / physiopathology
  • Staphylococcus aureus / drug effects*
  • Staphylococcus aureus / physiology

Substances

  • Anti-Bacterial Agents
  • Immunoconjugates